Clinical Trial Update: Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) 180mg When Added to PCSK9 Inhibitor Therapy [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating the added efficacy and safety of bempedoic acid (ETC-1002) 180 mg in combination with PCSK9 inhibitor therapy for hypercholesterolemia;…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypercholesterolemia

Drugs mentioned

• Bempedoic Acid (bempedoic acid)
• PCSK9 inhibitor (PCSK9 inhibitor)

Snippet

Sponsor: Esperion Therapeutics, Inc. | Conditions: Hypercholesterolemia | Phase 2 | Status: COMPLETED | Results posted: 2020-04-03